Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431699 | 0.92 | MGLL (0.51) | MGLLTRPM8TRPV1EPHX2 | |
| SCHEMBL2431708 | 0.92 | MGLL (0.51) | MGLLTRPM8TRPV1EPHX2 | |
| SCHEMBL12328249 | 0.89 | MGLL (0.48) | MGLLTRPM8TRPV1EPHX2 | |
| SCHEMBL2425006 | 0.88 | MGLL (0.44) | MGLLTRPM8EPHX2 | |
| SCHEMBL2344291 | 0.88 | MGLL (0.51) | MGLLEPHX2 | |
| SCHEMBL13363103 | 0.87 | MGLL (0.62) | MGLLTRPM8TRPV1FFAR4EPHX2 | |
| SCHEMBL2425964 | 0.86 | MGLL (0.41) | MGLLTRPM8EPHX2 | |
| SCHEMBL12295646 | 0.86 | MGLL (0.41) | MGLLTRPM8 | |
| SCHEMBL2427364 | 0.83 | MGLL (0.40) | MGLL | |
| SCHEMBL2428665 | 0.83 | MGLL (0.40) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | claimed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | claimed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | MGLL 246/4885TRPM8 1327/4885TRPV1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.